Roche
RO.SW
#44
Rank
NZ$571.38 B
Marketcap
NZ$718.17
Share price
0.65%
Change (1 day)
31.54%
Change (1 year)

P/E ratio for Roche (RO.SW)

P/E ratio at the end of 2025: 19.5

According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.2767. At the end of 2025 the company had a P/E ratio of 19.5.

P/E ratio history for Roche from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202519.5-28.11%
202427.260.17%
202317.0-25.96%
202222.9-4.18%
202123.943.67%
202016.7-10.72%
201918.71.8%
201818.3-16.13%
201721.813.42%
201619.3-15.17%
201522.712.39%
201420.248.81%
201313.612.51%
201212.112.65%
201110.713.12%
20109.47-34.15%
200914.426.54%
200811.4-18.81%
200714.0-33.93%
200621.2-19.79%
200526.492.13%
200413.7-62.1%
200336.3-297.73%
2002-18.3-218.88%
200115.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
28.7 41.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.9 8.10%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.0-6.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
27.6 36.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
25.3 24.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
17.1-15.71%๐Ÿ‡ซ๐Ÿ‡ท France
Becton Dickinson
BDX
46.6 129.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
35.3 74.18%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.1-35.56%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.